Daewoong Pharmaceutical’s NABOTA completed 3-phase clinical trial on muscle rigidity

Daewoong Pharmaceutical’s NABOTA completed 3-phase clinical trial on muscle rigidity - NABOTA has proved itself as a safe and effective treatment for stiffness in upper extremity muscles associated with adult stroke - The use of NABOTA expands beyond cosmetologic area to the treatment of post-stroke stiffness, broadening the selection base for doctors and patients Daewoong Pharmaceutical Co.,Ltd(President: Lee Jong-wook) announced on December 2 that it successfully completed 3-phase clinical trial aiming to prove safety and efficacy of NABOTA, a botulinum toxin type A formulation, for the treatment of stiffness in upper extremity muscles associated with adult stroke. The results of this 3-phase clinical trial would pave the way for NABOTA to expand its use into the therapeutic area related to the treatment of post-stroke stiffness in upper extremity muscles, as well as cosmetic treatment for wrinkles on the middle of forehead, thus broadening the selection base for doctors and patients. The post-stroke muscle stiffness, which occurs in one out of three stroke patients, is the after-effect caused by damage to cerebral motor center. Excessive muscle stiffness seriously disrupts day-to-day life and neurological and functional recovery of patient. Various treatments, such as medication, electrical therapy and surgery, have been used to alleviate post-stroke muscle stiffness. Recently, topical neuroblocking therapy using botulinum toxin has been widely used. NABOTA treats muscle stiffness associated with stroke by inhibiting the release of acetylcholine, a neurotransmitter, to mitigate muscle rigidity. Jeon Seung-ho, Director of Global Marketing, Daewoong Pharmaceutical, expressed high expectations, saying “The license is expected to be issued in late 2015. One out of three patients with post-stroke stiffness in muscles can be treated using botulinum toxin. Having successfully completed clinical trials, NABOTA will gain indications and wide acceptance in global botulinum toxin treatment market worth KRW 1.4 trillion, as well as domestic market for stroke treatment.

The release as fetched from its publisher. daewoong.co.kr ↗